HUTCHMEDHCM
About: HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Employees: 1,970
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
476% more call options, than puts
Call options by funds: $121K | Put options by funds: $21K
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
0.18% less ownership
Funds ownership: 1.01% [Q2] → 0.83% (-0.18%) [Q3]
2% less funds holding
Funds holding: 65 [Q2] → 64 (-1) [Q3]
7% less capital invested
Capital invested by funds: $151M [Q2] → $140M (-$11.1M) [Q3]
24% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 21
Research analyst outlook
We haven’t received any recent analyst ratings for HCM.
Financial journalist opinion
Based on 6 articles about HCM published over the past 30 days
![Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million](https://wsr-news.imgdelivr.io/O1FyXXok.jpg?w=640&h=360)
![HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy](https://wsr-news.imgdelivr.io/Hf7buNKN.jpg?w=640&h=360)
![Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales](https://wsr-news.imgdelivr.io/BtFRyzrt.jpg?w=640&h=360)
![HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture](https://wsr-news.imgdelivr.io/A4AJqSIY.jpg?w=640&h=360)
![HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)](https://wsr-news.imgdelivr.io/tDImmcQA.jpg?w=640&h=360)
![HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy](https://wsr-news.imgdelivr.io/tPvztJzK.jpg?w=640&h=360)
![Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer](https://wsr-news.imgdelivr.io/f9bHZMj4.jpg?w=640&h=360)
![HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer](https://wsr-news.imgdelivr.io/on3ajX5G.jpg?w=640&h=360)
![HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms](https://wsr-news.imgdelivr.io/kxYVkE9Q.jpg?w=640&h=360)
![HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan](https://wsr-news.imgdelivr.io/DXhtGNqS.jpg?w=640&h=360)